Cedars-Sinai, Rubedo Partner to Develop Targeted IPF Treatments

Cedars-Sinai, Rubedo Partner to Develop Targeted IPF Treatments

296234

Cedars-Sinai, Rubedo Partner to Develop Targeted IPF Treatments

Rubedo Life Sciences announced that it has partnered with Cedars-Sinai Medical Center, also in California, to advance its idiopathic pulmonary fibrosis (IPF) program and conduct collaborative research. The biopharmaceutical’s IPF program focuses on developing senolytics, or small molecules that target harmful senescent cells. These cells increase inflammation, fibrosis (tissue scarring), and contribute to age-related conditions, including pulmonary diseases like IPF. With this agreement, Cory Hogaboam, PhD, a professor of medicine and a research scientist with the…

You must be logged in to read/download the full post.